Answers are grounded in this paper and cite their sources.
Albinism is a rare genetic condition affecting approximately 1:17 000 newborns in Europe and North America. The disease is mainly characterized by poor vision, which is most often (but not always) presented with variable hypopigmentation of the hair, skin, and eyes. Visual abnormalities include foveal hypoplasia and retinal axon misrouting at the optic chiasm, resulting in reduced visual acuity and altered stereoscopic vision, respectively (Montoliu et al., 2014). Albinism can exist in isolation (non-syndromic) or in combination with additional system abnormalities (syndromic). Until relatively recently, the gene loci associated with albinism were limited to only a handful of genes encoding components of either the melanogenic pathway in pigment cells (for non-syndromic albinism) or the machinery responsible for the biogenesis of melanosomes—the organelles within which melanins are synthesized (for syndromic albinism). However, our understanding of the molecular causes of albinism has greatly expanded over the last few years to as many as 20 different gene loci (Table 1), including newly reported types of oculocutaneous albinism (OCA) (Montoliu et al., 2014) and some apparently unrelated syndromes such as foveal hypoplasia, optic nerve decussation defects, and anterior segment dysgenesis (FHONDA; Montoliu and Kelsh, 2014). Earlier this year, Ammann and colleagues added a new gene to the list by describing a new type of syndromic albinism associated with mutations in the AP3D1 and assigned to Hermansky–Pudlak syndrome (HPS) type 10 (HPS10). Syndromic types of albinism, such as HPS, result from defects in the formation of melanosomes and other lysosome-related organelles (LROs). LROs comprise a group of cell-type specific subcellular organelles that share some features with classical lysosomes but have unique components and morphological features that confer distinctive physiological functions. These functions include pigmentation, immunity, hemostasis, and lung plasticity, among others (Marks et al., 2013). Thus, in addition to the visual and pigmentation alterations due to defects in melanosome formation, HPS patients suffer from a complex disorder that always includes a tendency to bleed and/or bruise excessively (due to defects in the formation of platelet dense granules) and depending on the HPS subtype may also include lung fibrosis (due at least in part to defective lamellar bodies in lung epithelial cells), recurrent infections (due to a number of LRO defects in lymphocytes and dendritic cells and to neutropenia), granulomatous colitis, hemophagocytic lymphohistiocytosis (HLH), and/or cardiomyopathy (Wei and Li, 2013). Chediak–Higashi syndrome (CHS) is another type of syndromic albinism with a milder bleeding tendency but more severe immunodeficiency and lymphoproliferation, as well as neurological dysfunction. Both HPS and CHS are caused by mutations in genes encoding proteins that regulate intracellular trafficking steps common to the formation of multiple LROs. The genes affected in HPS encode subunits of four major cytoplasmic protein complexes: adaptor protein (AP)-3 and biogenesis of lysosome-related organelle complex (BLOC)-1, BLOC-2, and BLOC-3. Work in skin melanocytes indicates that AP-3, BLOC-1, and BLOC-2 function in the delivery of components from the biosynthetic pathway to melanosomes, whereas BLOC-3 functions mainly in a recycling pathway from melanosomes required to ‘rearm’ the forward pathways (Dennis et al., 2016; Marks et al., 2013). Mouse models corresponding to each of the known HPS variants exist and have been instrumental in better understanding these disorders. AP-3 is a heterotetrameric adaptor protein complex that reversibly associates with early endosomal membranes, and recognizes transmembrane proteins destined for lysosomes or LROs via exposed cytoplasmic sorting signals; it then packages these proteins into clathrin-coated transport vesicles for delivery to their destination (Marks et al., 2013). AP-3 exists in two forms, all of which include a single δ and either the σ3A or σ3B subunits. A ubiquitous AP-3A isoform additionally incorporates the β3A and μ3A subunits, whereas a neuronal-specific AP-3B isoform incorporates the β3B and μ3B subunits. Mutations in the AP3B1 gene, encoding the ubiquitously expressed β3A subunit, are associated with HPS2 and result in immunodeficiencies and lung fibrosis in addition to albinism and bleeding. A small subset of HPS2 patients also present with HLH due to defects in cytotoxic T-cell function, but in mouse models and most patients the HLH is transient (Jessen et al., 2013). Mutations in the Ap3d1 gene encoding the δ subunit were known in mice (mouse mutant mocha, listed in the IFPCS-ESPCR database color genes: http://www.espcr.org/micemut/), and result in neurological phenotypes in addition to those phenotypes seen in HPS2. However, the homologous mutation in the human AP3D1 gene had not been detected. “this patient displayed albinism, neutropenia, and immunodeficiency characterized by defects in cell-mediated cytolysis.” The identification of a new genetic target for syndromic albinism corresponding to a known mouse coat color gene raises the likelihood that additional HPS-related genes will be identified in the future (see Table 1). For example, mutations encoding additional subunits of AP-3 and BLOC-1 have not yet been associated with HPS-like pathologies in humans, even though mice with known mutations at some of the orthologous loci (e.g., cappuccino/Bloc1s4 and muted/Bloc1s5) have a clear HPS-like phenotype (Wei and Li, 2013). Moreover, a point mutation in the Vps33a gene, encoding a subunit of the HOPS/VPS-C complex that functions in endolysosomal fusion events, is found in a mouse HPS model (Wei and Li, 2013), and yet no corresponding mutation in a subunit gene for the corresponding human HOPS/VPS-C complex has been identified among syndromic albinism patients. More potential targets for disease will emerge from our increasing understanding of how these complexes function within cells. Therefore, the list of syndromic types of albinism will surely continue to grow in the forthcoming years.
No takes yet. Share an insight, caveat, or question.
Montoliu et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: